Literature DB >> 9199744

Evaluation of topical 0.03% flurbiprofen drops in the treatment of herpetic stromal keratitis.

R B Vajpayee1, B P Dhakal, S K Gupta, M S Sachdev, G Satpathy, S G Honavar, A Panda.   

Abstract

PURPOSE: The management protocol for herpetic stromal keratitis (HSK) is still controversial. We have attempted to compare the relative efficacy of topical dexamethasone 0.01% and flurbiprofen 0.03% in combination with topical acyclovir 3% in HSK.
METHODS: In this institutional, prospective, randomized, controlled, double-blind study, 45 clinically diagnosed cases of HSK were randomly distributed into three coded treatment groups--topical placebo, dexamethasone 0.01%, and flurbiprofen 0.03% each in tapering frequency and in combination with acyclovir 3% ointment five times per day for four weeks. Therapeutic response was assessed every third day for four weeks. Decoding of the treatment groups was done at the conclusion of the study and data analysed.
RESULTS: Four-week success rate was 93.3% (14 of 15) in the dexamethasone-acyclovir treatment group, 66.7% (10 of 15) in the flurbiprofen-acyclovir treatment group and 20% (3 of 15) in the placebo-acyclovir treatment group.
CONCLUSION: While dexamethasone in combination with acyclovir gives the best results in HSK with minimal side-effects, the role of topical flurbiprofen seems promising.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9199744     DOI: 10.1111/j.1442-9071.1996.tb01567.x

Source DB:  PubMed          Journal:  Aust N Z J Ophthalmol        ISSN: 0814-9763


  2 in total

Review 1.  Role of heparan sulfate in ocular diseases.

Authors:  Paul J Park; Deepak Shukla
Journal:  Exp Eye Res       Date:  2013-02-11       Impact factor: 3.467

Review 2.  A systematic review and meta-analysis to compare the efficacy of acyclovir 3% ophthalmic ointment to idoxuridine in curing herpetic keratitis by Day 7 of treatment.

Authors:  Diane E Balderson; Gengqian Cai; Michael A Fries; David M Kleinman; Megan M McLaughlin; Trupti M Trivedi; John I Wurzelmann; Sheila B Young
Journal:  BMC Ophthalmol       Date:  2015-04-17       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.